Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.

Cuzick J, Sestak I, Cella D, Fallowfield L; ATAC Trialists' Group.

Lancet Oncol. 2008 Dec;9(12):1143-8. doi: 10.1016/S1470-2045(08)70259-6. Epub 2008 Oct 29.

2.

Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV.

Mallolas J, Laguno M.

Expert Rev Anti Infect Ther. 2008 Jun;6(3):281-9. doi: 10.1586/14787210.6.3.281. Review.

PMID:
18588492
3.

Interferon: cellular executioner or white knight?

Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM.

Curr Med Chem. 2007;14(12):1279-89. Review.

PMID:
17504213
4.

Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.

Pau AK, McLaughlin MM, Hu Z, Agyemang AF, Polis MA, Kottilil S.

AIDS Patient Care STDS. 2006 Sep;20(9):612-9.

PMID:
16987047
5.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD.

Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.

PMID:
16908797
6.

Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons.

Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, Fullmer B, Wu L, Rehm CA, Masur H, Lane HC, Sherman KE, Fauci AS, Kottilil S.

J Infect Dis. 2006 Apr 15;193(8):1172-7. Epub 2006 Mar 13.

PMID:
16544259
7.

Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management.

Mauss S.

J Hepatol. 2006;44(1 Suppl):S114-8. Epub 2005 Dec 1. Review.

PMID:
16356579
8.

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

Voigt E, Schulz C, Klausen G, Goelz J, Mauss S, Schmutz G, Jessen H, Weitner L, Mutz A, Schranz D, Rockstroh JK; Kaad Study Group.

J Infect. 2006 Jul;53(1):36-42. Epub 2005 Nov 2.

PMID:
16269184
9.

Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness.

Sulkowski MS, Thomas DL.

AIDS. 2005 Oct;19 Suppl 3:S8-12. Review. No abstract available.

PMID:
16251833
10.

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR.

J Hepatol. 2005 Sep;43(3):425-33.

PMID:
15990196
11.

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID.

Gastroenterology. 2005 May;128(5):1437-44.

PMID:
15887125
12.

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.

Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières D, Saltz L, Leyden J.

Oncologist. 2005 May;10(5):345-56. Review.

13.

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.

Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP.

Ann Oncol. 2005 May;16(5):780-5. Epub 2005 Feb 22.

PMID:
15728108
14.

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team.

JAMA. 2004 Dec 15;292(23):2839-48.

PMID:
15598915
15.

Cytokines and psychopathology: lessons from interferon-alpha.

Capuron L, Miller AH.

Biol Psychiatry. 2004 Dec 1;56(11):819-24. Review.

PMID:
15576057
16.

Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin.

Farel C, Suzman DL, McLaughlin M, Campbell C, Koratich C, Masur H, Metcalf JA, Robinson MR, Polis MA, Kottilil S.

AIDS. 2004 Sep 3;18(13):1805-9.

PMID:
15316341
17.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J.

AIDS. 2004 Sep 3;18(13):F27-36.

PMID:
15316335
18.

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team.

N Engl J Med. 2004 Jul 29;351(5):451-9.

19.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.

20.

Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C.

Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P.

Neurosci Lett. 2004 Jul 22;365(2):87-91.

PMID:
15245784

Supplemental Content

Support Center